In June, the U.S. government halted the distribution of Eli Lilly‘s (NYSE: LLY) COVID-19 antibody cocktail. The problem was that the therapy didn’t seem to be effective against emerging coronavirus variants.
But now the U.S. is allowing Lilly’s antibody combo to be used once again in many states. In this Motley Fool Live video recorded on Sept. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Lilly’s COVID antibody therapy is making a comeback.